Baader Bank Aktiengesellschaft Celyad Oncology Sa Transaction History

Baader Bank Aktiengesellschaft

  • $1.63 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023
BUY
$0.0 - $0.96 $0 - $17,545
18,277 New
18,277 $0

About Celyad Oncology SA

CYAD Quotes by TradingView
  • Ticker CYAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 22,594,000
  • Market Cap $11.7M
  • Description
  • Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cance...
More about CYAD
Track This Portfolio

Track Baader Bank Aktiengesellschaft Portfolio

Follow Baader Bank Aktiengesellschaft and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baader Bank Aktiengesellschaft, based on Form 13F filings with the SEC.

News

Stay updated on Baader Bank Aktiengesellschaft with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email